Previous Close | 173.39 |
1-Year Change | 148.77% |
6-Months Change | 39.85% |
3-Months Change | 13.02% |
Moving Avg (50d) | 168.31 |
Moving Avg (200d) | 131.26 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 20.6B |
Beta (3-Years) | 1.47 |
Revenue Growth (ttm) | 27.41% |
Net Profit Margin (ttm) | -50.5% |
Return On Assets (ttm) | -34.52% |
EPS (ttm) | -4.52 |
PE Ratio (ttm) | -38.36 |
Dividend Yield | % |
Asset Description: | Natera, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-30 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
169.922 | 164.72 | 161.253 | 156.051 | 147.381 | 138.712 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Life Sciences Tools & Services |
Country: | United States |
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited... Wikipedia